Smart for Life (SMFL) Announces Letter of Intent to Acquire Largest Acquisition to Date.
6th Acquisition to Date is Expected to Add over $15 million of Revenue and to be Accretive to Earnings.
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
CB Scientific, Inc. (CBSC) Announces FDA 510(k) Submission.
CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor
Updated product to include significant...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
VERU Inc. (VERU) $24. High Risk, Minimal Reward?
Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders.
You Can't Kiss all the...
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Smart for Life (SMFL) Capitulates?
We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....
Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
Smart for Life (SMFL) $0.43 on Track to Close Pending Acquisition of Ceautamed Worldwide.
Has Smart for Life Found a Base at $0.45? Market Action Aside, We Think So. Report Out Monday.
Ohio State University Completes Study on Pressure Bioscience (PBIO) and Protein Drinks.
Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market.
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
